Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 2, 2008, Pages 169-171

  Bonnet, Eric ^a,b   Bernard, Jacques ^b   Fauvel, Josette ^a,b   Massip, Patrice ^b   Ruidavets, Jean Bernard ^a   Perret, Bertrand ^a,b  

^a INSERM   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE;

ALLELE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEIN C-III; BODY COMPOSITION; BODY FAT DISTRIBUTION; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FRANCE; GENE FREQUENCY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STAVUDINE; TRIGLYCERIDES;

EID: 39549103033     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0076     Document Type: Article

References (7)

1. Fauvel J, Bonnet E, Ruidavets JB, et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL in treated HIV patients. AIDS 2001;15:2397-2406.
2. Miserez A, Muller PY, Barella L, et al.: A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c is predictive of HIV-related hyperlipoproteinemia. AIDS 2001;15:2045-2048.
3. Nolan D, Moore C, Castley A, et al.: Tumor necrosis-alpha gene - 238G/A promoter polymorphism assoicated with a more rapid onset of lipodystrophy. AIDS 2003;17:121-123.
4. Tarr PE, Taffé P, Bleiber G, et al.: Modeling of the influence of apo C3, apo E, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005;191:1419-1426.
5. Guardiola M, Ferré R, Salazar J, et al.: Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T → C gene variation. Clin Chem 2006;52:1914-1919.
6. Bonnet E, Delpierre C, Sommet A, et al.: Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: Proposal of reference values for defining lipodystrophy. J Clin Densitom 2005;8:287-292.
7. Li WW, Dammerman MM, Smith JD, et al.: Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96: 2601-2605.